Overall Technical outlook

Business Operations:

Sector: Consumer Defensive
Industry: Household & Personal Products

Kenvue Inc. operates as a consumer health company in the United States, rest of North America, Europe, the Middle East, Africa, the Asia-Pacific, and Latin America. It operates in three segments: Self Care, Skin Health and Beauty, and Essential Health. The company offers over-the-counter medicine for cough, cold and allergy, pain care, digestive health, smoking cessation, and eye care, as well as other naturally inspired and self-care products, digital diagnostics, and telemedicine; face and body care, hair, sun, and other care products; oral and baby care, women's health, wound care, and other essential health products; tampons; cosmetics; and vitamins and supplements. It sells its products under the Benadryl, Calpol, Motrin, Nicorette, Rhinocort, Tylenol, Zarbee's Naturals, and Zyrtec; Aveeno, Dr.Ci:Labo, Le Petit Marseillais, Lubriderm, Neutrogena, OGX, and Rogaine; BAND-AID, Carefree, Desitin, Johnson's, Listerine, o.b., and Stayfree; and ORSL, Clean & Clear, Versalie, Benylin, Daktarin, Imodium, Johnson's Baby, Johnson's Adult, Maui Moisture, Microlax, Motilium, Neosporin, Neostrata, Pepcid, Pulmicort, Regaine, Sudafed, and Visine/Vispring/Visclear brands. Kenvue Inc. was incorporated in 2022 and is headquartered in Summit, New Jersey.

Revenue projections:

Revenue projections for KVUE
KVUE's projected revenue decline from last year is likely to make investors cautious. Lower revenues often hurt a company's bottom line, leading investors to be concerned about the company's ability to maintain profitability and deliver strong financial results in the future.

Financial Ratios:

currentRatio 1.005000
forwardPE 14.324776
debtToEquity 81.617000
earningsGrowth 0.085000
revenueGrowth 0.030000
grossMargins 0.584370
operatingMargins 0.194180
trailingEps 0.860000
forwardEps 1.239810

Kenvue Inc.'s current ratio, being 1.005, demonstrates that the company has the liquidity necessary to service its short-term debt. With strong cash reserves and current assets, Kenvue Inc. is well-equipped to meet its immediate financial obligations without any difficulties.
KVUE's Forward PE is within a good range, showing that the stock price compares well to its earnings. This suggests it isn't overpriced and leaves room for growth, making the stock appealing to investors looking for value and growth opportunities.
KVUE's high debt-to-equity ratio indicates a strong reliance on debt, meaning the company is heavily leveraged. This could increase financial risks if cash flow or earnings decline, making it more difficult for KVUE to manage its debt obligations.

Price projections:

Price projections for KVUE
The price of KVUE has regularly been close to the lower end of projections, suggesting that it might be struggling to meet market expectations. This trend raises questions about the company's future performance.

Insider Transactions:

Insider Transactions for KVUE

2 sell transactions of Kenvue Inc. were recorded, with market price hovering near 17.81999969482422.There were 1 buy transactions of KVUE stock, with market price at 17.329999923706055 per share.Increased sells at KVUE's current price levels point to a possible decline. If this trend of selling continues, it may signal that the stock's price will face further downward pressure, reflecting investor concerns.

Recommendation changes over time:

Recommendations trend for KVUE

Analysts' recent buy bias toward KVUE suggests the stock is gaining favor as a strong investment choice. This optimism could drive more investors to see KVUE as a smart place to invest, further bolstering confidence in the company's long-term growth and potential returns.